181 related articles for article (PubMed ID: 31811715)
21. Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study.
Bonaca MP; Lesén E; Giannitsis E; Hedberg J; Jernberg T; Lambrelli D; Duong M; Maggioni AP; Ariza-Solé A; Ten Berg J; Storey RF
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):701-708. PubMed ID: 37653447
[TBL] [Abstract][Full Text] [Related]
22. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
[TBL] [Abstract][Full Text] [Related]
23. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
Magnani G; Ardissino D; Im K; Budaj A; Storey RF; Steg PG; Bhatt DL; Cohen M; Oude Ophius T; Goudev A; Parkhomenko A; Kamensky G; Angiolillo DJ; López-Sendón J; Johanson P; Braunwald E; Sabatine MS; Bonaca MP
J Am Heart Assoc; 2021 Feb; 10(4):e017008. PubMed ID: 33559485
[TBL] [Abstract][Full Text] [Related]
24. Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV; Wolff R; Ramaekers BLT; Van Giessen A; Lang S; Ryder S; Worthy G; Duffy S; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 May; 36(5):533-543. PubMed ID: 29344794
[TBL] [Abstract][Full Text] [Related]
25. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
26. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.
Udell JA; Bonaca MP; Collet JP; Lincoff AM; Kereiakes DJ; Costa F; Lee CW; Mauri L; Valgimigli M; Park SJ; Montalescot G; Sabatine MS; Braunwald E; Bhatt DL
Eur Heart J; 2016 Jan; 37(4):390-9. PubMed ID: 26324537
[TBL] [Abstract][Full Text] [Related]
27. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
[TBL] [Abstract][Full Text] [Related]
28. Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
Tsaban G; Alnsasra H; El Nasasra A; Abu-Salman A; Abu-Dogosh A; Weissberg I; Golan YB; Barrett O; Westreich R; Aboalhasan E; Azuri J; Hammerman A; Arbel R
Am J Cardiovasc Drugs; 2022 Nov; 22(6):677-683. PubMed ID: 35869410
[TBL] [Abstract][Full Text] [Related]
29. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA;
Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629
[TBL] [Abstract][Full Text] [Related]
30. Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials.
Fanari Z; Malodiya A; Weiss SA; Hammami S; Kolm P; Weintraub WS
Cardiovasc Revasc Med; 2017; 18(1):10-15. PubMed ID: 27477306
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
[TBL] [Abstract][Full Text] [Related]
32. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
[TBL] [Abstract][Full Text] [Related]
34. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial.
Tomaniak M; Chichareon P; Modolo R; Takahashi K; Chang CC; Kogame N; Spitzer E; Buszman PE; van Geuns RM; Valkov V; Steinwender C; Geisler T; Prokopczuk J; Sabaté M; Zmudka K; Rademaker-Havinga T; Tijssen JGP; Jüni P; Hamm C; Steg PG; Onuma Y; Vranckx P; Valgimigli M; Windecker S; Baber U; Anderson R; Dominici M; Serruys PW
EuroIntervention; 2020 Apr; 15(18):e1605-e1614. PubMed ID: 31845894
[TBL] [Abstract][Full Text] [Related]
35. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
Cavallari I; Morrow DA; Creager MA; Olin J; Bhatt DL; Steg PG; Storey RF; Cohen M; Scirica BS; Piazza G; Goodrich EL; Braunwald E; Sabatine MS; Bonaca MP
Circulation; 2018 Feb; 137(7):684-692. PubMed ID: 29084737
[TBL] [Abstract][Full Text] [Related]
36. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Timmis A; Rapsomaniki E; Chung SC; Pujades-Rodriguez M; Moayyeri A; Stogiannis D; Shah AD; Pasea L; Denaxas S; Emmas C; Hemingway H
BMJ; 2016 Jun; 353():i3163. PubMed ID: 27334486
[TBL] [Abstract][Full Text] [Related]
37. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
Baber U; Dangas G; Angiolillo DJ; Cohen DJ; Sharma SK; Nicolas J; Briguori C; Cha JY; Collier T; Dudek D; Džavik V; Escaned J; Gil R; Gurbel P; Hamm CW; Henry T; Huber K; Kastrati A; Kaul U; Kornowski R; Krucoff M; Kunadian V; Marx SO; Mehta S; Moliterno D; Ohman EM; Oldroyd K; Sardella G; Sartori S; Shlofmitz R; Steg PG; Weisz G; Witzenbichler B; Han YL; Pocock S; Gibson CM; Mehran R
Eur Heart J; 2020 Oct; 41(37):3533-3545. PubMed ID: 33085967
[TBL] [Abstract][Full Text] [Related]
38. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.
De Filippo O; Cortese M; D Ascenzo F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Montefusco A; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Rinaldi M
Am J Cardiovasc Drugs; 2019 Aug; 19(4):381-391. PubMed ID: 31030413
[TBL] [Abstract][Full Text] [Related]
39. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
40. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
Storey RF; Angiolillo DJ; Bonaca MP; Thomas MR; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Braunwald E; Sabatine MS
J Am Coll Cardiol; 2016 Mar; 67(10):1145-1154. PubMed ID: 26965534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
